RegenxBio Inc (RGNX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】RegenxBio Inc (RGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10047)・商品コード:DATA904C10047
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:91
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology to develop product candidates. The company offers products for the treatment of metabolic, muscle, hematologic, ocular and neurodegenerative diseases and disorders. Its products also find application in the areas of gene therapy, gene modulation, protein therapeutics, genetic vaccines and protein screening. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc (RGNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RegenxBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RegenxBio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
REGENXBIO Raises USD70.5 Million in Series D Financing 13
REGENXBIO Raises USD30 Million in Series C Financing 16
REGENXBIO Raises USD7.9 Million in Venture Financing 18
ReGenX Biosciences Raises US$7.9 Million In Venture Financing 19
Partnerships 20
RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 20
Silverstein Foundation, RegenxBio and OrbiMed Advisors Form Joint Venture 21
ABL Enters into Contract Manufacturing Agreement with RegenxBio 22
Fidelity Biosciences Forms Joint Venture With ReGenX Biosciences 23
Licensing Agreements 24
Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 24
Ultragenyx Pharma Exercises Option for Licensing Agreement with Regenxbio 25
Prevail Therapeutics Enters into Licensing Agreement with RegenxBio 26
AveXis Enters into Licensing Agreement with Regenxbio 27
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 29
Biogen Enters into Licensing Agreement with RegenxBio 30
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 31
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 32
ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 34
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 35
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 36
ReGenx Enters Into Licensing Agreement With AAVLife 38
AveXis Amends Licensing Agreement With ReGenX Biosciences 39
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 40
ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 41
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 42
Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 43
ReGenX Biosciences Enters Into Licensing Agreement With Esteve 44
Equity Offering 45
RegenxBio Raises USD201.8 Million in Public Offering of Shares 45
RegenxBio Prices Public Offering of Shares for USD75.9 Million 47
RegenxBio Raises USD159.4 Million in IPO 49
Acquisition 51
RegenxBio to Acquire Dimension Therapeutics 51
RegenxBio Inc – Key Competitors 53
RegenxBio Inc – Key Employees 54
RegenxBio Inc – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 56
Strategy And Business Planning 56
May 15, 2018: REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation 56
Aug 09, 2017: The Silverstein Foundation, REGENXBIO, and OrbiMed Launch Prevail Therapeutics 57
Financial Announcements 58
Nov 07, 2018: REGENXBIO reports third quarter 2018 financial and operating results and announces initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II 58
May 08, 2018: REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights 61
Mar 06, 2018: REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights 63
Nov 08, 2017: REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights 65
Aug 08, 2017: REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 67
May 09, 2017: REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights 69
Mar 07, 2017: REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights 71
Jan 06, 2017: REGENXBIO Provides Year-End 2016 Corporate Update 73
Corporate Communications 75
May 29, 2018: REGENXBIO Names Alexandra Glucksmann As Board Director 75
Mar 28, 2017: REGENXBIO Enhances and Expands Scientific Leadership 76
Product News 77
Oct 26, 2018: REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting 77
Clinical Trials 81
Feb 08, 2018: REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 81
Sep 20, 2017: REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 82
Aug 11, 2017: REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists 83
Other Significant Developments 84
Oct 26, 2018: REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting 84
Jan 04, 2018: REGENXBIO Provides Year-End 2017 Corporate Update 88
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91

List of Tables
RegenxBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RegenxBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RegenxBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
REGENXBIO Raises USD70.5 Million in Series D Financing 13
REGENXBIO Raises USD30 Million in Series C Financing 16
REGENXBIO Raises USD7.9 Million in Venture Financing 18
ReGenX Biosciences Raises US$7.9 Million In Venture Financing 19
RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 20
Silverstein Foundation, RegenxBio and OrbiMed Advisors Form Joint Venture 21
ABL Enters into Contract Manufacturing Agreement with RegenxBio 22
Fidelity Biosciences Forms Joint Venture With ReGenX Biosciences 23
Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 24
Ultragenyx Pharma Exercises Option for Licensing Agreement with Regenxbio 25
Prevail Therapeutics Enters into Licensing Agreement with RegenxBio 26
AveXis Enters into Licensing Agreement with Regenxbio 27
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 29
Biogen Enters into Licensing Agreement with RegenxBio 30
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 31
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 32
ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 34
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 35
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 36
ReGenx Enters Into Licensing Agreement With AAVLife 38
AveXis Amends Licensing Agreement With ReGenX Biosciences 39
ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 40
ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 41
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 42
Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 43
ReGenX Biosciences Enters Into Licensing Agreement With Esteve 44
RegenxBio Raises USD201.8 Million in Public Offering of Shares 45
RegenxBio Prices Public Offering of Shares for USD75.9 Million 47
RegenxBio Raises USD159.4 Million in IPO 49
RegenxBio to Acquire Dimension Therapeutics 51
RegenxBio Inc, Key Competitors 53
RegenxBio Inc, Key Employees 54
RegenxBio Inc, Subsidiaries 55

List of Figures
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[RegenxBio Inc (RGNX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10047)販売に関する免責事項を必ずご確認ください。
★調査レポート[RegenxBio Inc (RGNX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆